Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Oracle Corporation (ORCL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Oracle Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Oracle Corporation trades at $138.85 (market cap $407.87B). The key difference: Oracle Corporation is far larger — about 90.8× ACADIA Pharmaceuticals Inc.'s market cap, and Oracle Corporation pays a 1.41% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ORCL | |
|---|---|---|
Market Cap | $4.49B | $407.87B |
Sector | Health | Technology |
52-Week High | $28.06 | $328.33 |
52-Week Low | $20.06 | $136.39 |
Enterprise Value | $3.69B | $537.12B |
Dividend Yield | — | 1.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Oracle (ORCL) trades at $143.76, up 2.49% today, with a bullish technical oscillator signal but bearish moving average trend. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.11 exceeding the $1.96 estimate. Revenue grew to $57.40 billion in 2025, and net income margin improved to 25.37%. Recent news highlights Oracle's AI infrastructure growth and partnership with OpenAI, driving investor optimism.
The outlook for Oracle is positive, supported by AI-driven demand and consistent earnings outperformance. Key risks include high debt levels and competitive pressures in cloud services. Analyst consensus is bullish with a $259 price target, suggesting significant upside from current levels, but investors should monitor execution on AI investments and macroeconomic conditions affecting tech spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
